Ranbaxy Laboratories may find it tough to revive its struggling US business in the face of accepting federal charges of selling adulterated drugs with intent to defraud and agreeing to pay $500 million to resolve false claim allegations, analysts ... Pharmacy Choice, 5 days ago
Agreeing to adulterated-drug charges to make US marketing tough for Ranbaxy [Financial Express (India)] - Pharmacy Choice, 6 days ago
Related to : Ranbaxy Laboratories Ltd Ranbaxy Laboratories Ltd BSE 14 May 13 | 12:00 AM 455.50 15.95 (3.63%) NSE 14 May 13 | 12:00 AM 455.65 15.95 (3.63%) For Ranbaxy Laboratories, the worst might not be over yet. Now, the Street is seeking a ...Smart Investor, 6 days ago
Related to : Ranbaxy Laboratories Ltd Ranbaxy Laboratories Ltd BSE 14 May 13 | 10:28 AM 441.65 2.1 (0.48%) NSE 14 May 13 | 10:25 AM 441.85 2.15 (0.49%) India's biggest drug maker, Ranbaxy Laboratories Limited, has agreed to pay $500 million ...Smart Investor, 1 week ago Ranbaxy to pay $500 mn to settle US fraud charges Smart Investor, 1 week ago
on your WebpageAdd Widget >Get your members hooked!